The diagnostic role of radionuclide imaging in evaluation of patients with nonhypersecreting adrenal masses(95 visite)(PDF pubblico134 visite) Maurea S, Klain M, Mainolfi C, Ziviello M, Salvatore M
Kloos, R.T., Gross, M.D., Francis, I.R., Korobkin, M., Shapiro, B., Incidentally discovered adrenal masses (1995) Endocr Rev, 16, pp. 460-484
Ross, M.S., Aron, D.C., Hormonal evaluation of the patient with an incidentally discovered adrenal mass (1990) N Engl J Med, 323, pp. 1402-1405
Francis, I.R., Gross, M.D., Shapiro, B., Integrated imaging of adrenal disease (1992) Radiology, 184, pp. 1-13
Lee, M.J., Mayo-Smith, W.W., Hahn, P.F., State-of-the-art MR imaging of the adrenal gland (1994) Radiographics, 14, pp. 1015-1029
Lamki, L.M., Tissue characterization in nuclear oncology: Its time has come (1995) J Nucl Med, 36, pp. 207-210
Shulkin, B.L., Wieland, D.M., Schwaiger, M., PET scanning with hydroxyephedrine: An approach to the localization of pheochromocytoma (1992) J Nucl Med, 33, pp. 1125-1131
Boland, G.W., Goldberg, M.A., Lee, M.J., Indeterminate adrenal mass in patients with cancer: Evaluation at PET with 2-[F-18]-fluoro-2-deoxy-D-glucose (1995) Radiology, 194, pp. 131-134
Fischman, A.J., Babich, J.W., Strauss, H.W., A ticket to ride: Peptide radiopharmaceuticals (1993) J Nucl Med, 34, pp. 2253-2262
Lamberts, S.W.J., Krenning, E.P., Reubi, J.C., The role of somatostatin and its analogs in the diagnosis and treatment of tumors (1991) Endocr Rev, 19, pp. 450-482
Maurea, S., Lastoria, S., Caracò, C., The role of radiolabeled somatostatin analogs in adrenal imaging (1996) Nucl Med Biol, 23, pp. 677-680
Soffer, L.J., Dorfam, R.J., Gabrilove, J.L., (1961) The Human Adrenal Gland, pp. 51-55. , Philadelphia, PA: Lea & Febiger
Shapiro, B., Gross, M.D., Sandler, M.P., Adrenal scintigraphy revisited: A current status report on radiotracers, clinical utility and correlative imaging (1987) Nuclear Medicine Annual, pp. 193-232. , Freeman LM, Weissman HS, eds. New York, NY: Raven Press
Tsukamoto, E., Itoh, K., Kanegae, K., Kobayashi, S., Koyanagi, Tamaki, N., Accumulation of iodine-131-iodocholesterol in renal cell carcinoma adrenal metastases (1998) J Nucl Med, 39, pp. 656-658
McEwan, A.J., Shapiro, B., Sisson, J.C., Radioiodobenzylguanidine for the scintigraphic location and therapy of adrenergic tumors (1985) Semin Nucl Med, 15, pp. 132-153
Petry, N.A., Shapiro, B., Radiopharmaceuticals for the endocrine system: Adrenomedullary imaging (1989) Pharmaceuticals in Medical Imaging, pp. 368-393. , Swanson D, Chilton H, Thrall JH, eds. New York, NY: MacMillan
Van Gils, A.P.G., Van Erkel, A.R., Falke, T.H.M., Pauwels, E.K.J., Magnetic resonance imaging or metaiodobenzylguanidine scintigraphy for the demonstration of paragangliomas? Correlations and disparities (1994) Eur J Nucl Med, 21, pp. 239-253
Sheps, S.G., Jiang, N.S., Klee, G.G., Diagnostic evaluation of pheochromocytoma (1988) Endocrinol Metab Clin North Am, 17, pp. 397-414
Copeland, P.M., The incidentally discovered adrenal mass (1983) Ann Intern Med, 98, pp. 940-945
Siren, J.E., Haapiainen, R.K., Huikuri, K.T., Incidentalomas of the adrenal gland: 36 Operated patients and review of literature (1993) World J Surg, 17, pp. 634-639
Caplan, R.H., Strutt, P.J., Wickus, G.G., Subclinical hormone secretion by incidentally discovered adrenal masses (1994) Arch Surg, 129, pp. 291-296
Tacchi, P.G., Bartoni, G., Gullà, P., Pheochromocytoma presenting as adrenal mass, symptomatic for large dimensions without sympathoadrenal signs: Report of two cases (1999) Int J Surg Sci, 6, pp. 62-64
Smit, A.J., Van Essen, L.H., Hollema, H., Meta-(I-13l)Iodobenzylguanidine uptake in a nonsecreting paraganglioma (1984) J Nucl Med, 25, pp. 984-986
Maurea, S., Reynolds, J.C., Cuocolo, A., I-131 MIBG uptake and urinary catecholamine levels in paragangliomas: Comparison of benign and malignant tumors (1991) Eur J Nucl Med, 18, p. 583
Mozley, P.D., Kim, C.K., Mohsin, J., Jatlow, A., Gosfield III, E., Alavi, A., The efficacy of iodine-123-MIBG as a screening test for pheochromocytoma (1994) J Nucl Med, 35, pp. 1138-1144
Miettinen, M., Neuroendocrine differentiation in adrenocortical carcinoma: New immunohistochemical findings supported by electron microscopy (1992) Lab Invest, 66, pp. 169-174
Hoefnagel, C.A., Metaiodobenzylguanidine and somatostatin in oncology: Role in the management of neural crest tumors (1994) Eur J Nucl Med, 21, pp. 561-581
Lynn, M.D., Shapiro, B., Sisson, J.C., Pheochromocytoma and the normal adrenal medulla: Improved visualization with 123-1-MIBG scintigraphy (1985) Radiology, 156, pp. 789-792
Hwang, I., Balingit, A.G., Georgitis, W.J., Sisson, J.C., Shapiro, B., Adrenocortical SPECT using iodine-131 NP-59 (1998) J Nucl Med, 39, pp. 1460-1463
Erasmus, J.J., Patz, E.F., McAdams, H.P., Evaluation of adrenal masses in patients with bronchogenic carcinoma using F-18 fluorodeoxy-glucose positron emission tomography (1997) AJR, 168, pp. 1357-1360
Maurea, S., Mainolfi, C., Bazzicalupo, L., Imaging of adrenal tumors using F-18 FDG PET: Comparison of benign and malignant lesions (1999) AJR, 173, pp. 25-29
Minn, H., Joensuu, H., Ahonen, A., Klemi, P., Fluorodeoxyglucose imaging: Method to assess the proliferative activity of human cancer in vivo - Comparison with DNA flow cytometry in bead and neck tumors (1988) Cancer, 61, pp. 1776-1781
Yankaskas, B.C., Staab, E.V., Cravem, M.B., Delayed complications from fine-needle biopsies of solid masses of the abdomen (1986) Invest Radiol, 21, pp. 325-328
Shreve, P.D., Stevenson, R.S., Deters, E.C., Kison, P.V., Gross, M.D., Wahl, R.L., Oncologic diagnosis with 2-[fluorine-18]fluoro-2-deoxy-D-glucose intaging: Dual-head coincidence gamma camera versus positron emission tomographic scanner (1998) Radiology, 207, pp. 431-437
The aim of this study was to evaluate the role of radionuclide imaging in the characterization of nonhypersecreting adrenal masses. Methods: A total of 54 patients (19 men, 35 women; mean age, 50 ± 16 y) with nonhypersecreting unilateral adrenal tumors that had been originally detected on CT or MRI underwent adrenal scintigraphy using different radiotracers. None of the patients showed specific symptoms of adrenal hypersecretion. Screening tests for excess cortical and medullary products showed normal adrenal hormone levels. Radionuclide studies (n = 73) included 131l-norcholesterol (n = 24), 131l-metaiodo-benzylguanidine (MIBG) (n = 23), and 18F-FDG PET (n = 26) scans. Results: Histology after surgery (n = 31) or adrenal biopsy (n = 23) was obtained. Adrenal lesions were represented by 19 adenomas, 4 cysts, 1 myelolipoma, 1 neurinoma, 2 ganglioneuromas, 5 pheochromocytomas, 4 pseudotumors, 6 carcinomas, 2 sarcomas, and 10 metastases (size range, 1.5- to 5-cm diameter; mean, 4.9 ± 3.1 cm). For norcholesterol imaging, diagnostic sensitivity, specificity, and accuracy were 100%, 71%, and 92%, respectively; the positive predictive value (PPV) of the norcholesterol scan to characterize an adrenal mass as an adenoma was 89%, whereas the corresponding negative predictive value (NPV) to rule out this type of tumor was 100%. For MIBG imaging, diagnostic sensitivity, specificity, and accuracy were 100%, 94%, and 96%, respectively; the PPV of the MIBG scan to characterize an adrenal mass as a medullary chromaffin tissue tumor was 83%, whereas the corresponding NPV to rule out this type of tumor was 100%. For FDG PET, diagnostic sensitivity, specificity, and accuracy were 100%, 100%, and 100%, respectively; the PPV of FDG PET to characterize an adrenal mass as a malignant tumor was 100%, whereas the corresponding NPV to rule it out was 100%. Furthermore, in 7 patients with malignant adrenal tumors, FDG whole-body scanning revealed extra-adrenal tumor sites (n = 29), allowing an accurate diagnosis of the disease's stage using a single-imaging technique. Conclusion: In patients with nonhypersecreting adrenal masses, radionuclide adrenal imaging, using specific radiopharmaceuticals such as norcholesterol, MIBG, and FDG, may provide significant functional information for tissue characterization. Norcholesterol and MIBG scans are able to detect benign tumors such as adenoma and pheochromocytoma, respectively. Conversely, FDG PET allows for recognition of malignant adrenal lesions. Therefore, adrenal scintigraphy is recommended for tumor diagnosis and, hence, for appropriate treatment planning, particularly when CT or MRI findings are inconclusive for lesion characterization.
Ntziachristos V, Cuénod CA, Fournier L, Balvay D, Pradel C, Siauve N, Clement O, Jouannot E, Lucidarme O, Vecchio SD, Salvatore M, Law B, Tung C-H, Jain RK, Fukumura D, Munn LL, Brown EB, Schellenberger E, Montet X, Weissleder R, Clerck ND, Postnov A * Tumor Imaging(124 visite) Textbook Of In Vivo Imaging In Vertebrates (ISSN: 9780-4700), 2007 Jul 16; 1: 277-309. Impact Factor:1.148 DettagliEsporta in BibTeXEsporta in EndNote
Aloj L, Aurilio M, Rinaldi V, D'Ambrosio L, Tesauro D, Peitl PK, Maina T, Mansi R, Von Guggenberg E, Joosten L, Sosabowski JK, Breeman WA, De Blois E, Koelewijn S, Melis M, Waser B, Beetschen K, Reubi JC, De Jong M * The EEE project(130 visite) Proc Int Cosm Ray Conf Icrc Universidad Nacional Autonoma De Mexico, 2007; 5(HEPART2): 977-980. Impact Factor:0 DettagliEsporta in BibTeXEsporta in EndNote
Hesse B, Tagil K, Cuocolo A, Anagnostopoulos C, Bardies M, Bax J, Bengel F, Busemann Sokole E, Davies G, Dondi M, Edenbrandt L, Franken P, Kjaer A, Knuuti J, Lassmann M, Ljungberg M, Marcassa C, Marie PY, Mckiddie F, O'connor M, Prvuolovich E, Underwood R * 3. 0 T perfusion MR imaging(305 visite) Rivista Di Neuroradiologia (ISSN: 1120-9976), 2004; 17(6): 807-812. Impact Factor:0.023 DettagliEsporta in BibTeXEsporta in EndNote
235 Records (224 escludendo Abstract e Conferenze). Impact factor totale: 689.659 (660.926 escludendo Abstract e Conferenze). Impact factor a 5 anni totale: 807.67 (777.494 escludendo Abstract e Conferenze).
ibb.cnr.it